A review of articles on geriatric topics from 2017 and 2018 revealed evidence supporting exercise for the elderly, early mobility for hospitalized patients, and oral anticoagulant therapy for atrial fi brillation to support cognitive function, and evidence against antipsychotic drugs for dementia-associated behaviors. No silver bullet was found for Alzheimer prevention or therapy.
U
nfortunately, recent research has not unveiled a breakthrough for preventing or treating cognitive impairment or Alzheimer disease. But several studies from the last 2 years are helping to drive the fi eld of geriatrics forward, providing evidence of what does and does not help a variety of issues specifi c to the elderly.
Based on a search of the 2017 and 2018 literature, this article presents new evidence on preventing and treating cognitive impairment, managing dementia-associated behavioral disturbances and delirium, preventing falls, and improving inpatient mobility and posthospital care transitions.
■ COGNITIVE IMPAIRMENT, DEMENTIA: STILL NO SILVER BULLET
With the exception of oral anticoagulation treatment for atrial fi brillation, there is little evidence that pharmacologic or nonpharmacologic interventions slow the onset or progression of Alzheimer disease.
Nonpharmacologic interventions
Home occupational therapy. A 2-year homebased occupational therapy intervention 1 showed no evidence of slowing functional decline in patients with Alzheimer disease. The randomized controlled trial involving 180 participants consisted of monthly sessions of an intensive, well-established collaborative-care management model that included fall prevention and other safety strategies, personalized training in activities of daily living, exercise, and education. Outcome measures for activi-ties of daily living did not differ signifi cantly between the treatment and control groups.
1
Physical activity. Whether physical activity interventions slow cognitive decline and prevent dementia in cognitively intact adults was examined in a systematic review of 32 trials.
2 Most of the trials followed patients for 6 months; a few stretched for 1 or 2 years.
Evidence was insuffi cient to prove cognitive benefi t for short-term, single-component or multicomponent physical activity interventions. However, a multidomain physical activity intervention that also included dietary modifi cations and cognitive training did show a delay in cognitive decline, but only "low-strength" evidence.
2
Nutritional supplements. The antioxidants vitamin E and selenium were studied for their possible cognitive benefi t in the doubleblind randomized Prevention of Alzheimer Disease by Vitamin E and Selenium trial 3 in 3,786 asymptomatic men ages 60 and older. Neither supplement was found to prevent dementia over a 7-year follow-up period.
A review of 38 trials 4 evaluated the effects on cognition of omega-3 fatty acids, soy, ginkgo biloba, B vitamins, vitamin D plus calcium, vitamin C, beta-carotene, and multi-ingredient supplements. It found insuffi cient evidence to recommend any over-the-counter supplement for cognitive protection in adults with normal cognition or mild cognitive impairment.
Pharmacologic treatments
Testosterone supplementation. The Testosterone Trials tested the effects of testosterone gel vs placebo for 1 year on 493 men over age 65 with low testosterone (< 275 ng/mL) and with subjective memory complaints and objective memory performance defi cits. Treatment was not associated with improved memory or other cognitive functions compared with placebo.
5
Antiamyloid drugs. A randomized, double-blind, placebo-controlled trial in nearly 2,000 patients evaluated verubecestat, an oral beta-site amyloid precursor protein-cleaving enzyme-1 inhibitor that reduces the amyloidbeta level in cerebrospinal fl uid. 6 Verubecestat did not reduce cognitive or functional decline in patients with mild-tomoderate Alzheimer disease, while adverse events including rashes, falls, injuries, sleep disturbances, suicidal ideation, weight loss, and hair color change were more common in the treatment groups. The trial was terminated early because of futility at 50 months.
And in a placebo-controlled trial of solanezu mab, a monoclonal antibody directed against the amyloid beta peptide, no benefi t was demonstrated at 80 weeks in more than 2,000 patients with Alzheimer disease. Multiple common agents. A well-conducted systematic review 8 of 51 trials of at least a 6-month duration did not support the use of antihypertensive agents, diabetes medications, nonsteroidal anti-infl ammatory drugs, aspirin, hormones, or lipid-lowering drugs for cognitive protection for people with normal cognition or mild cognitive impairment.
However, some studies found reassuring evidence that standard therapies for other conditions do not worsen cognitive decline and are protective for atrial fi brillation. Proton-pump inhibitors. Concern exists for a potential link between dementia risk and proton-pump inhibitors, which are widely used to treat acid-related gastrointestinal disorders. 9 A prospective population-based cohort study 10 of nearly 3,500 people ages 65 and older without baseline dementia screened participants for dementia every 2 years over a mean period of 7.5 years and provided further evaluation for those who screened positive. Use of proton-pump inhibitors was not found to be associated with dementia risk, even with high cumulative exposure.
Results from this study do not support avoiding proton-pump inhibitors out of concern for dementia risk, although long-term use is associated with other safety concerns.
Oral anticoagulation. The increased risk of dementia with atrial fi brillation is well documented.
11
A retrospective study 12 based on a Swedish health registry and using more than 444,000 patients covering more than 1.5 million years at risk found that oral anticoagulant treatment at baseline conferred a 29% lower risk of dementia in an intention-to-treat analysis and a 48% lower risk in on-treatment analysis compared with no oral anticoagulation therapy. No difference was found between new oral anticoagulants and warfarin.
No cognitive benefi ts found for vitamins B, C, D, and E, selenium, testosterone gel, or omega-3 fatty acids KIM AND HASHMI

Transcatheter aortic valve implantation is not associated with cognitive decline
For patients with severe aortic stenosis who are not surgical candidates, transcatheter aortic valve implantation is superior to standard medical therapy, 13 but there are concerns of neurologic and cognitive changes after the procedure.
14 A meta-analysis of 18 studies assessing cognitive performance in more than 1,000 patients (average age ≥ 80) after undergoing the procedure for severe aortic stenosis found no signifi cant cognitive performance changes from baseline perioperatively or 3 or 6 months later. 
Antipsychotics are not recommended
Antipsychotics are often prescribed, 16 although they are associated with metabolic syndrome 17 and increased risks of stroke and death. 18 The FDA has issued black box warnings against using antipsychotics for behavioral management in patients with dementia. Further, the American Geriatrics Society and the American Psychiatric Association do not endorse using them as initial therapy for behavioral and psychological symptoms of dementia. 16, 19 The Centers for Medicare and Medicaid Services partnered with nursing homes to improve the quality of care for patients with dementia, with results measured as the rate of prescribing antipsychotic medications. Although the use of psychotropic medications declined after initiating the partnership, the use of mood stabilizers increased, possibly as a substitute for antipsychotics.
20
Dextromethorphan-quinidine use is up, despite modest evidence of benefi t A consumer news report in 2017 stated that the use of dextromethorphan-quinidine in long-term care facilities increased by nearly 400% between 2012 and 2016. 21 Evidence for its benefi ts comes from a 10-week, phase 2, randomized controlled trial conducted at 42 US study sites with 194 patients with probable Alzheimer disease. Compared with the placebo group, the active treatment group had mildly reduced agitation but an increased risk of falls, dizziness, and diarrhea. However, rates of adverse effects were low, and the authors concluded that treatment was generally well tolerated. 
Pimavanserin: No long-term benefi t for psychosis
In a phase 2, randomized, double-blind, placebo-controlled trial in 181 patients with possible or probable Alzheimer disease and psychotic symptoms, pimavanserin was associated with improved symptoms as measured by the Neuropsychiatric Inventory-Nursing Home Version psychosis score at 6 weeks, but no difference was found compared with placebo at 12 weeks. The treatment group had more adverse events, including agitation, aggression, peripheral edema, anxiety, and symptoms of dementia, although the differences were not statistically signifi cant. 23 
■ DELIRIUM: AVOID ANTIPSYCHOTICS
Delirium is common in hospitalized older adults, especially those who have baseline cognitive or functional impairment and are exposed to precipitating factors such as treatment with anticholinergic or narcotic medications, infection, surgery, or admission to an intensive care unit.
24
Delirium at discharge predicts poor outcomes In a prospective study of 152 hospitalized patients with delirium, those who either did not recover from delirium or had only partially recovered at discharge were more likely to visit the emergency department, be rehospitalized, or die during the subsequent 3 months than those who had fully recovered from delirium at discharge. 
Prophylactic haloperidol does not improve outcomes
In a multicenter randomized, double-blind, placebo-controlled trial, van den Boogaard et al studied prophylactic intravenous haloperidol in nearly 1,800 critically ill patients at high risk of delirium. 27 Haloperidol did not improve survival at 28 days compared with placebo. For secondary outcomes, including delirium incidence, delirium-free and comafree days, duration of mechanical ventilation, and hospital and intensive care department length of stay, treatment was not found to differ statistically from placebo.
Antipsychotics may worsen delirium
A double-blind, parallel-arm, dose-titrated randomized trial, conducted at 11 Australian hospices or hospitals with palliative care services, administered oral risperidone, haloperidol, or placebo to 247 patients with lifelimiting illness and delirium. Both treatment groups had higher delirium symptom scores than the placebo group. 28 In addition, a systematic review and metaanalysis of 19 studies found no benefi t of antipsychotic medications for preventing or treating delirium in hospitalized adults.
29
Antipsychotics are often continued indefi nitely A retrospective chart review at a US academic health system found 30 that among 487 patients with a new antipsychotic medication prescribed during hospitalization, 147 (30.2%) were discharged on an antipsychotic. Of these, 121 (82.3%) had a diagnosis of delirium. Only 15 (12.4%) had discharge summaries that included instructions for discontinuing the drug.
Another US health system retrospectively reviewed antipsychotic use and found 31 that out of 260 patients who were newly exposed to an antipsychotic drug during hospitalization, 146 (56.2%) were discharged on an antipsychotic drug, and 65% of these patients were still on the drug at the time of the next hospital admission.
■ EXERCISE, EXERCISE, EXERCISE Exercise recommended, but not vitamin D, to prevent falls In 2018, the US Preventive Services Task Force updated its recommendations for preventing falls in community-dwelling older adults. 32 Based on the fi ndings of several trials, the task force recommends exercise interventions for adults age 65 and older who are at increased risk for falls. Gait, balance, and functional training were studied in 17 trials, resistance training in 13, fl exibility in 8, endurance training in 5, and tai chi in 3, with 5 studies including general physical activity. Exercise interventions most commonly took place for 3 sessions per week for 12 months (range 2-42 months).
The task force also recommends against vitamin D supplementation for fall prevention in community-dwelling adults age 65 or older who are not known to have osteoporosis or vitamin D defi ciency.
Early mobilization helps inpatients
Hospitalized older adults usually spend most of their time in bed. Forty-fi ve previously ambulatory patients (age ≥ 65 without dementia or delirium) in a Veterans Affairs hospital were monitored with wireless accelerometers and were found to spend, on average, 83% of the measured hospital stay in bed. Standing or walking time ranged from 0.2% to 21%, with a median of only 3% (43 minutes a day). 33 Since falls with injury became a Centers for Medicare and Medicaid Services nonreimbursable hospital-acquired condition, tension has arisen between promoting mobility and preventing falls. 34 Two studies evaluating the adoption of mobility-restricting approaches such as bed-alarms, "fall-alert" signs, supervision of patients in the bathroom, and ensuring patients' walking aids are within reach, did not fi nd a signifi cant reduction in falls or fallrelated injuries. 35, 36 A clinically signifi cant loss of community mobility is common after hospitalization in older adults. 37 Older adults who developed moAvoid antipsychotics for dementia or delirium KIM AND HASHMI bility impairment during hospitalization had a higher risk of death in a large, retrospective study. 38 A large Canadian multisite intervention trial 39 that promoted early mobilization in older patients who were admitted to general medical wards resulted in increased mobilization and signifi cantly shorter hospital stays.
■ POSTHOSPITAL CARE NEEDS IMPROVEMENT
After hospitalization, older adults who have diffi culty with activities of daily living or complex medical needs often require continued care. About 20% of hospitalized Medicare benefi ciaries in the United States are discharged to skilled nursing facilities. 40 This is often a stressful transition, and most people have little guidance on selecting a facility and simply choose one based on its proximity to home. 41 A program of frequent visits by hospitalemployed physicians and advanced practice professionals at skilled nursing facilities resulted in a signifi cantly lower 30-day readmission rate compared with nonparticipating skilled nursing facilities in the same geographic area. 42 Home healthcare is recommended after hospital discharge at a rapidly increasing rate. Overall referral rates increased from 8.6% to 14.1% between 2001 and 2012, and from 14.3% to 24.0% for patients with heart failure. 43 A qualitative study of home healthcare nurses found a need for improved care coordination between home healthcare agencies and discharging hospitals, including defi ning accountability for orders and enhancing communication. 44 
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